Listen
Reason for request
Inclusion on the list of medicines approved for hospital use in the extension of the indication “relapsed/refractory chronic lymphocytic leukaemia combined with chemotherapy”.
-
Clinical Benefit
| Substantial |
There are drug and non-drug alternatives (haematopoietic stem cell transplantation); The actual benefit is substantial. |
Clinical Added Value
| moderate |
In the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia, MABTHERA combined with chemotherapy brings a moderate improvement in actual benefit (ASMR III), in terms of efficacy in the therapeutic strategy. |
English version
Contact Us
Évaluation des médicaments
